The Role of Selected lncRNAs in Lipid Metabolism and Cardiovascular Disease Risk

被引:1
作者
Gluba-Sagr, Anna [1 ]
Franczyk, Beata [1 ]
Rysz-Gorzynska, Aleksandra [2 ]
Olszewski, Robert [3 ]
Rysz, Jacek [1 ]
机构
[1] Med Univ Lodz, Dept Nephrol Hypertens & Family Med, PL-90549 Lodz, Poland
[2] Med Univ Lodz, Dept Ophthalmol & Visual Rehabil, PL-90549 Lodz, Poland
[3] Natl Inst Geriatr Rheumatol & Rehabil Warsaw, Dept Gerontol Publ Hlth & Didact, PL-02637 Warsaw, Poland
关键词
long noncoding RNA; lipid disorders; atherosclerosis; LONG NONCODING RNA; HIGH-DENSITY-LIPOPROTEIN; CORONARY-ARTERY-DISEASE; PROMOTES ATHEROSCLEROSIS; CHOLESTEROL HOMEOSTASIS; UP-REGULATION; EXPRESSION; BINDING; ACCUMULATION; MECHANISMS;
D O I
10.3390/ijms25179244
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Lipid disorders increase the risk for the development of cardiometabolic disorders, including type 2 diabetes, atherosclerosis, and cardiovascular disease. Lipids levels, apart from diet, smoking, obesity, alcohol consumption, and lack of exercise, are also influenced by genetic factors. Recent studies suggested the role of long noncoding RNAs (lncRNAs) in the regulation of lipid formation and metabolism. Despite their lack of protein-coding capacity, lncRNAs are crucial regulators of various physiological and pathological processes since they affect the transcription and epigenetic chromatin remodelling. LncRNAs act as molecular signal, scaffold, decoy, enhancer, and guide molecules. This review summarises available data concerning the impact of lncRNAs on lipid levels and metabolism, as well as impact on cardiovascular disease risk. This relationship is significant because altered lipid metabolism is a well-known risk factor for cardiovascular diseases, and lncRNAs may play a crucial regulatory role. Understanding these mechanisms could pave the way for new therapeutic strategies to mitigate cardiovascular disease risk through targeted modulation of lncRNAs. The identification of dysregulated lncRNAs may pose promising candidates for therapeutic interventions, since strategies enabling the restoration of their levels could offer an effective means to impede disease progression without disrupting normal biological functions. LncRNAs may also serve as valuable biomarker candidates for various pathological states, including cardiovascular disease. However, still much remains unknown about the functions of most lncRNAs, thus extensive studies are necessary elucidate their roles in physiology, development, and disease.
引用
收藏
页数:32
相关论文
共 163 条
  • [1] New and Emerging Risk Factors for Coronary Heart Disease
    Akhabue, Ehimare
    Thiboutot, Jeffrey
    Cheng, Jeh-wei
    Vittorio, Timothy J.
    Christodoulidis, Georgios
    Grady, Kathleen M.
    Lerakis, Stamatios
    Kosmas, Constantine E.
    [J]. AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2014, 347 (02) : 151 - 158
  • [2] Noncoding RNAs and Atherosclerosis
    Aryal, Binod
    Rotllan, Noemi
    Fernandez-Hernando, Carlos
    [J]. CURRENT ATHEROSCLEROSIS REPORTS, 2014, 16 (05)
  • [3] Dynamic regulation of circulating microRNA during acute exhaustive exercise and sustained aerobic exercise training
    Baggish, Aaron L.
    Hale, Andrew
    Weiner, Rory B.
    Lewis, Gregory D.
    Systrom, David
    Wang, Francis
    Wang, Thomas J.
    Chan, Stephen Y.
    [J]. JOURNAL OF PHYSIOLOGY-LONDON, 2011, 589 (16): : 3983 - 3994
  • [4] Effects of torcetrapib in patients at high risk for coronary events
    Barter, Philip J.
    Caulfield, Mark
    Eriksson, Mats
    Grundy, Scott M.
    Kastelein, John J. P.
    Komajda, Michel
    Lopez-Sendon, Jose
    Mosca, Lori
    Tardif, Jean-Claude
    Waters, David D.
    Shear, Charles L.
    Revkin, James H.
    Buhr, Kevin A.
    Fisher, Marian R.
    Tall, Alan R.
    Brewer, Bryan
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (21) : 2109 - 2122
  • [5] miRNA therapeutics: a new class of drugs with potential therapeutic applications in the heart
    Bernardo, Bianca C.
    Ooi, Jenny Y. Y.
    Lin, Ruby C. Y.
    McMullen, Julie R.
    [J]. FUTURE MEDICINAL CHEMISTRY, 2015, 7 (13) : 1771 - 1792
  • [6] Bhat Shakil Ahmad, 2016, Noncoding RNA Res, V1, P43, DOI 10.1016/j.ncrna.2016.11.002
  • [7] RNA Interference (RNAi)-Based Therapeutics: Delivering on the Promise?
    Bobbin, Maggie L.
    Rossi, John J.
    [J]. ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 56, 2016, 56 : 103 - 122
  • [8] Lipotoxicity in the heart
    Borradaile, NA
    Schaffer, JE
    [J]. CURRENT HYPERTENSION REPORTS, 2005, 7 (06) : 412 - 417
  • [9] Focus on high-density lipoproteins in reducing cardiovascular risk
    Brewer, HB
    [J]. AMERICAN HEART JOURNAL, 2004, 148 (01) : S14 - S18
  • [10] The SREBP pathway: Regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor
    Brown, MS
    Goldstein, JL
    [J]. CELL, 1997, 89 (03) : 331 - 340